Wealth Alliance Advisory Group LLC Buys 964 Shares of Eli Lilly and Company $LLY

Wealth Alliance Advisory Group LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 18.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,106 shares of the company’s stock after buying an additional 964 shares during the quarter. Eli Lilly and Company comprises about 1.1% of Wealth Alliance Advisory Group LLC’s holdings, making the stock its 23rd largest position. Wealth Alliance Advisory Group LLC’s holdings in Eli Lilly and Company were worth $6,562,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Maryland Capital Advisors Inc. acquired a new stake in Eli Lilly and Company during the 4th quarter worth about $25,000. Miller Global Investments LLC bought a new position in shares of Eli Lilly and Company in the 4th quarter worth about $33,000. Dorato Capital Management acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $36,000. Vermillion & White Wealth Management Group LLC lifted its stake in shares of Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after purchasing an additional 16 shares during the period. Finally, 10Elms LLP boosted its position in shares of Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after purchasing an additional 10 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

LLY stock opened at $874.14 on Wednesday. The business has a 50-day simple moving average of $952.17 and a two-hundred day simple moving average of $986.25. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The company has a market capitalization of $825.91 billion, a P/E ratio of 38.09, a price-to-earnings-growth ratio of 1.03 and a beta of 0.51. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company’s quarterly revenue was up 42.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts expect that Eli Lilly and Company will post 33.9 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on LLY. JPMorgan Chase & Co. lifted their target price on Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a report on Tuesday, March 10th. The Goldman Sachs Group set a $1,260.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, February 5th. TD Cowen boosted their target price on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. Finally, Morgan Stanley increased their target price on shares of Eli Lilly and Company from $1,313.00 to $1,327.00 and gave the stock an “overweight” rating in a research note on Friday, April 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,216.52.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to acquire Ajax Therapeutics for up to $2.3B, adding a JAK2 inhibitor for myelofibrosis and expanding its oncology/hematology pipeline—a diversification away from GLP‑1 reliance. Lilly Agrees To Buy Ajax Therapeutics For Up To $2.3 Billion
• Positive Sentiment: Lilly struck a multi‑program AI/genetic‑medicine deal with Profluent worth up to ~$2.25B to accelerate DNA‑editing and enzyme design—this boosts R&D productivity potential and could lift long‑term valuation if programs advance. Eli Lilly’s AI Genetic Medicine Deal And What It Means For Valuation
• Positive Sentiment: Analysts remain bullish overall (e.g., reiterated Overweight/price targets following recent acquisitions), providing support that fundamentals and pipeline diversification justify a premium. Analysts Reiterate Bullish Outlook on Eli Lilly
• Neutral Sentiment: Investors will watch Q1 results for high‑level trends, but management won’t provide detailed Foundayo launch metrics in the earnings release—so the quarter may not settle near‑term launch questions. Eli Lilly investors are eager for Foundayo insight after early launch data
• Negative Sentiment: Early launch data show Lilly’s oral Foundayo is tracking behind Novo Nordisk’s Wegovy pill (Citi/IQVIA prescription data), raising concerns about market share, pricing pressure and near‑term revenue trajectory for GLP‑1s. GLP-1 pill race heats up as Wegovy tablet holds strong against Lilly rival
• Negative Sentiment: Competitor Boehringer reported late‑stage obesity results showing meaningful weight loss (~16.6%), adding competitive pressure to Lilly’s obesity franchise and intensifying investor scrutiny of future GLP‑1 pricing and share. Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial
• Negative Sentiment: Leerink lowered its price target (from $1,296 to $1,058), signaling some analyst recalibration of upside given near‑term launch risks—this can amplify selling pressure even as many analysts remain constructive. Leerink Partners adjusts PT on Eli Lilly

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.